ابيضاض الدم ذو الخلايا الزغبية الكلاسيكي عند الانتكاس بعد العلاج الأولي بمناظر نيوكليوسيد البيورين

References

• In the absence of renal impairment or active infection, therapy should consist of a standard regimen of a purine nucleoside analog (either cladribine or pentostatin).
• If previous remission was >60 months, consider re-treatment with initial therapy.
• If previous remission was >24 months, then consider re-treatment with a purine analog possibly combined with an anti-CD20 monoclonal antibody, or a clinical trial.
• If previous remission was <24 months, consider alternative therapy, including investigational agents, after confirming accuracy of diagnosis.
• Older therapeutic approaches may still offer benefit (eg, interferon alpha, splenectomy, rituximab).
• Patients in complete response should have near normalization of peripheral blood counts: hemoglobin >11 g/dL (without transfusion), platelets >100,000/mL, and an absolute neutrophil count >1,500/mL.
• There should be regression of splenomegaly by physical examination.

DOI: 10.1182/blood-2016-01-689422